5HVH
Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with two Inhibitory Nanobodies
Summary for 5HVH
| Entry DOI | 10.2210/pdb5hvh/pdb |
| Related | 5HVF 5HVG |
| Descriptor | Carboxypeptidase B2, VHH-a204, VHH-i83, ... (6 entities in total) |
| Functional Keywords | procarboxypeptidase u, thrombin-activatable fibrinolysis inhibitor, tafi, procarboxypeptidase r, plasma procarboxypeptidase b, nanobody, antibody fragment, protein complex, hydrolase/hydrolase inhibitor, hydrolase-hydrolase inhibitor complex |
| Biological source | Homo sapiens (Human) More |
| Total number of polymer chains | 3 |
| Total formula weight | 75380.38 |
| Authors | Zhou, X.,Weeks, S.D.,Strelkov, S.V.,Declerck, P.J. (deposition date: 2016-01-28, release date: 2016-06-22, Last modification date: 2024-10-16) |
| Primary citation | Zhou, X.,Weeks, S.D.,Ameloot, P.,Callewaert, N.,Strelkov, S.V.,Declerck, P.J. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity. J.Thromb.Haemost., 14:1629-1638, 2016 Cited by PubMed Abstract: Essentials Thrombin-activatable fibrinolysis inhibitor (TAFI) is a risk factor for cardiovascular disorders. TAFI inhibitory nanobodies represent a promising step in developing profibrinolytic therapeutics. We have solved three crystal structures of TAFI in complex with inhibitory nanobodies. Nanobodies inhibit TAFI through distinct mechanisms and represent novel profibrinolytic leads. PubMed: 27279497DOI: 10.1111/jth.13381 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (3 Å) |
Structure validation
Download full validation report
